Q4 2019 Earnings Call

The next available conference specialist will be with you momentarily.

[music].

Oh.

Oh for something might have you named please.

First lien baby last name wrong.

[noise] [noise] [noise].

Now what company with Mr. Brown.

Hi, Robert A.I.E.R.A.

Okay, and you're calling for a pulse.

Yes right.

Okay joining right.

Brian tearing adipose stimulation technology, Ngs technology delivers nanosecond pulses of electrical energy to non thermally clear cells, while sparing adjacent non cellular tissue.

On today's call I'll provide updates on our collaboration with the FDA and our current regulatory strategy for cell effects system.

And we'll share information on our recent presence and continued engagement and scientific community, but I will discuss delek developments and plans for our clinical programs and then Sandy will provide the fourth quarter and full year 2019 financial results. Finally, I will conclude and open the call for Q anyway.

To begin I would like to recapture year filled with accomplishments representative of our growth as a company and the creation of a solid foundation from which we will launch our platform technology.

The cornerstone of this foundation is this strong body of clinical evidence that we have produced demonstrating the excellent safety and efficacy profile of NPS technology for aesthetic dermatology.

In 2019, we enrolled 373 subjects in our clinical studies treating over 1800 lesions, which is up from only 108 enrolled in 2018 treating 408 lesions, bringing our total for the end of 2019 to 552 subjects and 2600 50 lesions.

This is a tremendous amount of important data and with each study completed our conviction in the clinical utility of NPS grows.

Through this clinical work, we have developed a large network of leading aesthetic dermatologists, who are participating in our studies and presenting data at important scientific meetings.

This data has been the backbone of 12 podium presentations delivered throughout the year at the most prominent aesthetic dermatology conferences, including the American Society for laser medicine in surgery, The American Academy of Dermatology and American Society of Dermatologic surgery.

The attendance and interest at these sessions has been strong and played an important rolling increasing the awareness of NPS technology among physicians.

Along with these presentations we've had three manuscripts published in the German journal of Dermatologic surgery in the American Society for lasers in surgery in medicine, both of which are leading peer reviewed journals in this space.

The positive outcomes demonstrated throughout this extensive clinical work has created a strong group of key opinion leader advocates for our proprietary nano Paul stimulation technology.

On the product side, we have been hard at work enhancing our cell effects system and the proprietary sell effects cloud software that enables our novel and proprietary utilization based business model.

From our industry experience and extensive market research, we've been able to design the delivery system and unique business model that aligns the interest of patients practices and the company.

This is accomplished by allowing practices to purchase and download cycle units to their system that are then used to treat individual lesions.

The system tracks this utilization and captures relevant usage data.

We understand that patients want to pay based on the number of lesions treated and dermatologists wants to treat patients regardless of the amount size or type of lesions and one costs aligned with a specific treatments.

Selling the cell effects system was designed to facilitate this type of lesion based or utilization based business model and removes friction that can exist in the more typical consumable or single use disposable based medical device business model.

Additionally, the cell effects cloud will serve as a practice management tool, helping physicians understand utilization data practice metrics and manage customers and a web based portal that also provide software application and maintenance updates. The Celtics system represents the next generation energy modality device combined with current color.

Wow software capabilities in an easy to use platform that will integrate seamlessly into existing aesthetic dermatology practices.

In 2019 pulse Biosenses began preparations for commercialization outside the United States by successfully completing ISO 13 for 85 2016 quality system management certification.

ISO which stands for the international organization for standardization is an independent organization that provides common standards to facilitate world trade.

The ISO 13, 45, 2016 certification specifies requirements for our quality management system, Oregon, where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements throughout every step of of products lifecycle.

The ISO 13 45 standard is the medical device the industry's most widely used international standards for quality management and has a necessary an important step when preparing to market products for many countries outside the United States.

So we have not outline the priority and timing of countries, we expect to market to sell effects as demand outside the United States. ISO 13, 45 certification is the first step in this process and a significant milestone for the company.

For European Union countries. This is the first step in pursuing a CE mark for medical device, which is similar to an FDA clearance in the European Union.

We expect to begin the CE mark process for the Teleflex system in 2020 and will provide timelines for the CE Mark process in future communications.

As an organization in 2019, we also added to our leadership team to support our next phase of growth, we brought on sand Sandy Gardner as CFO to lead the finance team. She brings years of experience as a CFO for other publicly traded aesthetic medical device companies.

Simultaneously as we grow our operational infrastructure to support eventual commercialization, we will take steps to build out the commercial team.

We have started at the leadership level by promoting aesthetic dermatology experts at Evers to executive Vice President General manager Dermatology and hiring Bob Tyson as Vice President of sales North America, as we get closer to commercialization, we will continue to add to this team.

This group has been instrumental in developing our unique business model and sales strategy. They will continue with market research to ensure we will hit the ground running once our system received clearance.

Now I'll provide an update on our path to commercialization.

Here are efforts efforts are focused on achieving FDA five 10-K clearance for use of the cell effects system and aesthetic dermatology because we are introducing a novel energy based modality that is different from currently available dermatologic treatments and has the ability to treat conditions that are not adequately addressed by other solutions the regulatory.

Sorry path is one that is determined in collaboration with FDA and we continue to work with FDA on the best path forward.

It's clear from the conclusion of our recent five 10-K and follow on discussions with FDA that we're on the right track and pursuing a five 10-K clearance for the cell effects system and we now believe as stepwise approach starting with a five 10-K for a general Dermatologic indication followed by additional five 10-K submissions for specific indicate.

Ones is the best approach and should lead to a more protect predictable regulatory process.

We are in regular communication with FDA and in the last several weeks, we have had a number of informal and productive conversations.

As the next step we're planning a formal meeting call to Q sub to discuss the data requirements for a five 10-K submission for general Dermatologic indication.

We have filed a formal request for the Q seven meeting that included our proposal for the data requirements of this submission.

We're pleased to FDA has accepted our request and we are working to finalize a date for the Q seven meeting in May.

Our intention for this meeting is to agree on the data required for fighting case submission for general Dermatologic indication for the cell effects system.

Once we are clear on the data requirements, which we hope will be the result of the meeting our plan is to generate the data necessary for a new 510 key submission and get the submission in the FDA.

Based on our assumptions today, we estimate it will take approximately four months to compile the data and reports and resubmit of five 10-K to FDA. Once we have clarity on what will be required one of the benefits of this simplified approach is that the submission should be relatively straightforward for FDA to review potentially leading to a clearance by the end of the year.

On a parallel path, we plan to have additional meetings with FDA to discuss specific indication clearance and the comparative study data that would be required for this separate submission, we anticipate starting with tenacious hyperplasia and expect that study to begin in Q3.

I will now turn the call over to add to provide more details on our continued engagement with the scientific dermatology community.

Thanks, Darren and good afternoon, everyone.

MPS technology has shown the unique capability to precisely cleared common skin lesions with desirable outcomes that current thermal modalities cannot achieve.

The NPS differences due to the Nonthermal mechanism of the nanoparticles of energy affecting cellular structures of skin lesions, while sparing the surrounding non cellular dermis.

Excitement around NPS technology in the dermatology community is growing we continue to build a broad base of scientific evidence proving the utility of NPS technology cellular specificity across multiple applications for conditions aesthetic dermatology seat in the clicks today at high volumes, but Jeff.

We go one treated due to the inability of current modalities to produce desirable aesthetic outcomes.

In addition to the continuing podium presentations on NPS technology at major medical meetings throughout the year.

NPS technology and pulse Biossance have been honored by the publication of three compelling clinical setting articles in peer reviewed journals in the second half from 2019.

Among these journals are lasers in surgery in medicine, which is the official journal of American Society for laser medicine in surgery or elements.

This publication is of the highest quality research and clinical scientific journal articles for which positions in researchers that specialize in energy based technologies, especially particularly the application to receive and read on a regular basis.

The August issue of lasers, and Mexican surgery feature manuscript authored by Dr., David Kaufman and dairy from American titled a dose response study of a novel method of selective tissue modification of cellular structures in the skin lift nanopass electric fields.

This peer reviewed articles prove the ability of non thermal NPS energy to affect always assign restructure skin tissue and having no effect on the surrounding non similar tissue.

With predictable dose response effects over a wide range of energy settings.

The same data was honored by S. LMS the previous shared with a best of basic Science and Translational Research Award a stood at distinction that earned this further recognition as a full journal article in this prestigious journal.

Next the journal of Dermatologic surgery publishes the latest most expensive and in depth scientific content devoted to cosmetic and reconstructive skin surgery and skin cancer and is to peer reviewed publication of the prestigious American society of Dermatologic surgery or eight ssds.

In October Dermatologic surgery, published an article titled Safety and efficacy of Nanosecond post and look we'll feel treatment of sebaceous glands hyperplasia.

Featuring Dermatologic surgeon, Dr. Gilly, when the valley as lead author.

That move values on member of our scientific Advisory Board and has been a consulting offer or investigator in more than 100 caramel.

Dermatology Journal articles.

And 16 medical textbooks for the dermatology specialty.

Also in Dermatologic surgery.

Another article titled Safety, and efficacy of nano pulses stimulation in the treatment of patients with severe care doses was published in December with Dr. George crews on as lead author Dr. Roof that is a clear president of the American Academy of Dermatology, former President and American spending Dermatologic surgery, and past President of American Society.

The for lasers medicine in surgery Doctor, who that is considered a world wide authority in the use of energy devices.

Both of these clinic article substantiate the sound science and ability of NPS technology to clear SH and SK lesions with an excellent safety profile and high level of patient satisfaction.

Article represents to work of some of the most respected skin specialists in the world.

Looking ahead, we continue to gain recognition for our scientific progress buyer investigators with podium presence at medical conferences throughout the world.

Recently and international podium presentation with given by Dr. Gilliam with only at the International Masters course on aging again this past January in parish.

That Camilla Morbelli discuss clinical and histological findings from a study using NPS technology in treating challenging cases of nodular basal cell carcinoma.

Basal cell carcinoma core BCC is the most common form of skin cancer worldwide.

The nodular subtype reported in this study comprises 60% evolve basal cell carcinoma.

For these deep Nustar legions. The current standard of care is surgical excision, which can lead to large permanence cars.

This NPS feasibility study demonstrated clinical photographs and histology, suggesting elimination of a treated bazell cells and favorable cosmetic outcomes and a reduced potential for scar formation compared to the current standard of care for these types of skin cancers.

Our technology has already been similar to recognized at seven medical meetings in January and February this year.

And we expect to continue to receive invitations for prestigious investigators and researchers speak on NPS technology at medical meetings as they occur.

This continuing validation in both peer reviewed publications and putting invitations at medical meetings helps build credibility for technology.

We feel this recognition confirms that our strategy of working with key opinion leaders to generate high quality clinical research enhances our profitability for commercial success in the future.

The positive and unique properties on NPS technologies are being discussed and announced throughout the aesthetic dermatology community. We have been successful and raising awareness of our differentiated technology as physicians are quite excited about the potential of a non thermal energy device to address challenging skin conditions. We.

Feel this is a strong indication of the future market opportunity for MPS.

In summary, and to build on what Darren mentioned previously through our extensive work with our network of leading investigators and cable Els in dermatology. We have now treated 3126 lesions from 627 clinical study participants as of March.

For representing an exceptional safety and efficacy profile across a wide range of patients ages skin types leasing varieties and tissue conditions. We continued to demonstrate that our unique sell specific mechanism as broad utility in dermatology plastic surgery and.

Other medical applications are growing portfolio of 99 patents is unparalleled in the energy device category and on long term ability to build a dominant position for the use of Nana pulse energy in medical applications continues to expand.

The growing scientific recognition and peer efficacy of NPS technology is a strong predictor of commercial acceptance in the future.

Now I'll turn the call back to there.

Thanks, Ed I'd like to quickly touch on the clinical programs, we have underway to expand the application pipeline furthest along as our non genital warts pivotal study. We are pleased to report we have completed enrollment and are tracking. According to plan words represented very difficult lesion for dermatologists to treat the rate of success in a single treatment is low and.

The condition, usually requires multiple treatments and a sub optimal outcome. We're excited to offer physicians a better option to treat the many patients they see with words.

Additional feasibility work is being done in back acne and basal cell carcinoma, we look forward to providing updates on these studies when available.

Taking a step back we would like to acknowledge the difficult and trying circumstances presented by the cobot 19 outbreak.

The safety and health of our employees as our top priority.

And observation of the recommendations from government and health authorities, we have taken the appropriate precautions to ensure the safety of everyone that pulls bio sciences.

At this point none of these actions have had an impact on our operations, we're particularly encouraged that our interactions with FDA have moved forward without an issue and we look forward to our upcoming Q sub teleconference. This.

This is an extremely fluid situation and we will continue to monitor closely.

Now I'm excited to introduce our new CFO Sandy Gardner. It has been great to have are on board. Since you began in late November to remind you. She brings prior CFO experience from other public aesthetic medical device companies and we have appreciated for immediate positive impact for the first time I will turn the call over to Sandy Gardner for an update.

On our financials.

Thank you Dan and it's great to join the strong team and Paul biased science and I'm very excited about the company's opportunity to intensities, a proprietary technology in static dermatology market and expand into additional applications in the future.

Turning now to the fourth quarter financial cash cash equivalents and investments totaled 25.4 million as at December 30 parents 2019, compared to 34.5 million as of September Thirtyth 2019 cash in the fourth quarter totaled 9.1 million dollar.

Yes.

Operating expenses for the three months ended December 31st 2019, or $13.9 million compared to $9.9 million for the prior year period, the increase in operating expenses, driven by expansion and operational infrastructure, including marketing and sales function.

As long as expansion of the research and development team and clinical trial costs.

Net loss for the quarter ended December 31 2019.

Teen point $8 million compared to $9 million for the quarter ended December 31, 2018 for the full year 2019 cash usage totaled $34.2 million.

Operating expenses for the full year ended December 31, 2019 were $48 million compared to $38 million in 2018. The increase in operating expenses was driven by expansion and operational infrastructure, including marketing and sales functions.

Well the expansion as the research and development team and clinical trial costs.

Net loss for the full year 2019, with $47 million compared to $37.5 million in 2018 in February we announced the board of directors had approved a rights offering to raise an additional $30 million now I will turn the call back.

Back over to Darrin for closing remarks.

Thank you Sandy to conclude we have made significant strides as a company over the past year. We've conducted many clinical studies generating an enormous amount of positive clinical data on the safety and efficacy profile of MPS technology, and our cell effects system elevated our standing in the scientific community through 12 podium presentations on our two.

Acknowledge the by top Callebs in the field had three peer reviewed articles published and finalize development of the cell effects system with a proprietary cloud infrastructure to support a unique utilization based business model.

All these things are important to the ultimate commercial success of the cell effects system.

We believe that ones have FDA clearances achieved the value will be realized by the company our customers and patients.

Our confidence in the long term success of Paulsboro Sciences has only increased through 2019, and we're excited about the opportunity ahead.

Joining me joining me now for Q in a is Evers executive Vice President General manager Dermatology, and Sandy gardener Executive Vice President and Chief Financial Officer, Operator lets open the call for questions.

Thank you.

I'd like to ask your question. Please press star one I knew telephone keypad and confirmation terminal indicate your line is in the question can you.

You may start to if you would like to remove your question from the Q and for participant GC Speaker Clinton and may be necessary to pickup handset before pressing the star and keys.

Our first question is from Sean Khan with H.C. Wainwright. Please proceed.

Hi, Thanks for taking my question.

This is Sean tangible Arcadia, Yes, hi, HQ remain.

My first question is about.

Operating expenses then.

Kashagan me, so I saw that it was about.

20% quarter over quarter, increasing Jamie.

And.

Some increasing R&D as well should we expect a moderate increase in 2020 and beyond.

So we said.

Sorry, this is standing and nice to niculae over the phone.

So we are operating expenses, we expect to remain largely consistent in between 19 versus 2019, because we have been fully staffed as you know started the second half of last year that we hired our commercial organizations that we that Ics.

As those increases to actually common in the second half of 2019 that now we are at a stable base and we've been at that same operating expense level and cash utilization has been in the eight to 9 million per quarter, and we do expect that to stay consistent at least until the back half.

As the year.

I see thank you that's very helpful and one last question is I think I heard that.

You plan to start off hyperplasia studying the quick.

Yes, So hey, Schon this is Darren.

This is our best estimate at this particular time I as I mentioned. This this is something that we intend to meet with FDA on.

In advance of starting that study of course.

And working through the details of what that study will look like and just.

As a reminder to those that have been following us.

Coming out of.

The last five to MKS and preparing for the next I think that sebaceous hyperplasia study will be one where we do a comparative trial and and so it will be important for us to work with FDA on that which is what we expect to do.

Okay sounds good.

Nickel.

Okay, Great Hey, I'd also like to mention quickly that our chairman Bob Dugan is also on the line in available to answer questions.

Our next question is from Brian Kravitz private Investor. Please proceed.

Hi, guys.

I had a question in regards to the rights offering.

Hi.

You out a little Colorado timeline on when that might happen was part of my question.

And part BMI question as you mentioned the five point.

Five 10-K general could be available and perform on what does that mean for commercialization.

Sure So I'll address.

Rights offering and then handed over to Darren. So there are certain components that we have to complete before we filed a registration statement with the FCC. We our goal is to complete all those elements by the end as this month or early April and submit that to the FCC and that then.

That would initiate the registration statement for the rights offering.

So hey, this is Derek and I'll comment on the FDA.

Just to kind of lay that out again so.

Yeah.

Based on conversations again informal conversations that we've had with FDA, we think that.

This is going after a general dermatologic indication as a first step really makes the most sense. So we have subsequently submitted a request for acute what's called a Q submission or Q sub meeting.

Fortunately FDA has been very responsive and gotten back to us I mean, it looks like that meeting is going to happen now in may.

That will be a teleconference with FDA, so coming out of that meeting, which we hope will.

We'll kind of solidify the requirements.

For a general Dermatologic indication, then we'll finalize data that needs to be generated for that and prepare five 10-K to be submitted.

And our expectation is that that five 10-K would be submitted and approximately four months. After the meeting if we're able to solidify those requirements at that meeting now until we have that formal meeting we won't know exactly.

What those requirements will be or what we will need to do for that five 10-K.

But our assumption today is that that we have a pretty good understanding of what would be expected and at that meeting will result in the solidification of that and so.

If you take that and then four months after that you.

Assume a five 10-K submission.

Then its towards the end of the year and our goal would certainly be to try to get in before the end of the year five 10-K clearance.

The general Dermatologic indication for the Celtics system.

Okay. Thank you.

Yes. Thank you.

As a reminder, just star one on your telephone keypad. If you would like to ask the question. Our next question is from Michael Fox with parents to the capital. Please proceed.

Hi, Thanks for taking my call everybody.

Can you say, Mike about how you doing there.

Alright.

Great could you talk about kind of the just a little bit more color and kind of give us a flavor of the tone of the conversations with the FDA and then also.

And in how how it transpired with general.

Dermatology path and then.

Given that we've been working with the FDA for quite some time do we get in the.

It does it benefit us that we've been working with them for a while or we just really starting at scholar one on this application.

Yes. Thanks, those those are all really good question, so I think.

My my feeling is that all the interactions Weve had.

With the FDA up until now benefit us going forward. So I think where we're at is kind of coming out of this last slide 10-K is that.

FDA is.

We have gotten I think very good.

Signs from FDA at that they believe that this is a five 10-K device. So I think that is extremely positive I think that.

We under.

They believe that because of all the data and everything we've done in the past 510, K. So I think that for one is very positive. It shows that they have oh, a pretty good understanding of the technology itself and what we're trying to do with it.

Where we ended with the last submission as we described on a previous call. It I think it our press release was that the clinical data that we provided just didnt give them.

Enough to.

To be able to come to a substantial equivalents conclusion in terms of the benefit risk and largely.

Where they ended up was that they wanted to see comparative data and so really I think all the data we provided has been very informative.

Helped FDA I understand this technology, which again is a new technology for them. So I think it's it takes time for reviewers to to really begin to understand the technology and how it can be used.

In the skin and now we have I think some pretty good clarity on.

Kind of what their expectations will be with regard to specific clinical indications. The idea of a general a general dermatologic indication came about through conversation with FDA and I think really their desire that.

That we introduced this technology through the FDA in kind of a stepwise approach because it allows them.

To provide clearances and to perform reviews of the technology in a kind of a more digestible.

Form so when we do the general derm indication.

Our expectation is that will be a relatively small amount of data.

In addition, today that we provided previously and then with each new specific indication that will really be largely based on that clinical data and so I think.

You know kind of through this.

All this work we've been doing with an FDA I think what we've realized is that for a new technology like this.

It makes you know.

It's a lot easier for them to kind of do this in a stepwise approach and for us to provide data in that kind of step wise approach and that's that's kind of really where we're at so I think the last five 10-K, we provided a lot of information to clinical studies worth and a lot of preclinical data.

And so now from that we're kind of going in a more stepwise fashion and I think.

The other thing were doing coming out of that is to have these Q submission meetings. So I think those are our ability to to sit with FDA to agree on kind of the requirements of the data prior to anything being submitted to FDA and so I think all those things.

Put us in a very good position going forward and I've been involved in.

A number of new technologies, New medical device technologies in my career I think most notably in the medical Robotics field, where we introduced the first at FDA cleared robot to the market and it. It takes time and I think is the lesson as you're going with as you're introducing these new technologies to.

Viewers that have never seen it before to work through that process and.

I think thats, what we've experienced for sure over the last 12 months or so.

And I think it definitely benefit this going forward were much further along than we were.

Prior and I think we have a much better understanding of.

The requirements that FDA is wanting and I think they have a much better understanding of the technology.

Today so.

Hopefully that helps.

Yes, Thats, great and then one follow up the number of County Wells that you guys. Currently has that are supportive of the device. How does that played to the FDA is.

Decision or pass and or does it at all.

I don't.

There is no kind of formal.

There's nothing formalize that FDA would lean on with regard to.

Okay wells that are involved in our clinical studies, they certainly are aware.

And they have seen our publication so there's certainly aware.

Folks that have been involved and I think they do.

Have a lot of respect for them that being said.

Hey has their own internal medical officers and they rely largely on those medical officers.

For these types of things.

Okay, great. Thanks, a lot.

Thanks, a lot like.

So eight so since we're I'm here I think.

I would like to ask.

Bob If you wouldn't mind make it a few comments.

Since we got you on the line fortunate enough to have you on the line today and no questions have come up specifically, maybe you could make a few comments.

Yes, Thank you Dan it's.

My pleasure, Thank you Sandy and the team have been very.

Forthright in describing where we're at our current condition.

In my opinion the the.

At the a challenge has appreciated just how well the company is doing across other important divisions and departments, including marketing sales service manufacturing.

Q way.

Advancing development of the product we've got a spectacular team they've performed really well.

The care wells that have joined and the number of presentations in the work they've done is highly unusual for product has yet to be cleared.

It shows the enthusiasm and their reach I think to the FDA. We've had no event that had to be reported no event.

In addition for patients that that.

Not resolve overtime.

In that regard, it's all been good we well over 2000 lesions treated so we certainly harbor no concerns consideration doubts the reservation that our product is effective with the needed. Its wanted details are saying the same thing and I think weve appropriately are going after the correct indication now.

Which is why there and was able to collapse the time by by a good six months.

Between now and getting a good clearance with regard to.

Brian's question on on the the rights offering I'm hopeful it occurs within the next 90 days.

We will give you more of an update.

Redo, our filing which should take place met early part of as of April.

That would be subject to.

See review, but given that our 10-K, then and all of our filings have gone without question or for the scrutiny from the FCC.

If we do not receive any concern back from them there will be less than that on a day period, we're going to set the price where all current shareholders have a right through to participate I will do our best to encourage them to do so my former company Pharmacyclics during a very dry period of 2000.

Today, 2009, red 85% participation without actually the crisis stock.

Appreciate it during the period of time, Robert no warrants or extra.

Sure.

Value other than just our common stock I'm I'm very excited about.

Participating I'm very excited about the company's future.

Clearly no one knows and appreciate an equity that goes down in price of Warren Buffett said that says when his favorite company. He licensee them depreciate price not many bustan up and say the same thing, but we've got a great company with a very bright future top notch people.

They are being patient here there they are sticky right to the project that they have in hand, and I I predict very very a bright future for everybody involved including our current shareholders. So those view that have been a long the stock for quite a while your patience is appreciated it does.

Take a while I just noticed that thing thing some of the great companies in America have hit some challenges in stocks have lost a lot of their value, including my former Pharmacyclics Amazon.

Apple with Steve jobs things happen that you don't want or anticipate good people work their way through it just like the country's working its way through Corona buyers, we will work our way through our issues. There there are a baby fraction of the Corona virus, but.

Yeah, I'm quite positive and if there's any question.

I can be reached or you're going to them or be now be happy to respond.

Okay, Darren macro back over to you all have you already we're participating for the team yeah really appreciate it.

Thanks, Rob I appreciate your jumping on the call with us and with that I think we will.

All right with that I think we will close operator. Thank you everybody for joining the call. We very much appreciate your support and we will keep you apprised of our progress.

Thank you. This does conclude today's conference you may disconnect. Your lines at this time and thank you for your participation.